Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
I.V. dressing is basically transparent dressing used to protect I.V. sites or catheters to the insertion point and can also be used as secondary dressings. I.V. dressing allow the excess moisture while maintaining a moist wound healing environment which is necessary for wound healing and help to block the germs and keep catheter site dry and clean.
IV Dressing that consist of micro porous non-woven fabric (Polyethylene film), medical hypo-allergenic adhesive and absorbent pads.
Rising incidences of infections such as central line associated bloodstream infection (CLABSI), catheter-related bloodstream infection (CRBSI), and other infections are expected to boost growth of the I.V. dressing market over the forecast period. For instance, according to the data published in National Healthcare Safety Network’s Bloodstream Infection Surveillance in March 2018, around 30,000 CLABSI cases are reported every year in the U.S. CLABSI infection can prolong the hospital stay of the patients, which can increase the cost burden on patients and may also lead to mortality.
Furthermore, according to the International Society for Infectious Diseases: March 2018, around 250,000 cases of blood stream infections are reported every year in the U.S. Among these cases, around 80,000 are catheter-related bloodstream infections (CRBSI), which occur in intensive care units.
The global I.V. dressing market is estimated to be valued at US$ 724.2 million in 2021 and is expected to exhibit a CAGR of 5.7% over the forecast period (2021-2028).
Figure 1. Global I.V. Dressing Market Share (%) in Terms of Value, By Region, 2021
Increasing prevalence of chronic kidney diseases and significant number of dialysis procedures is expected to drive the market growth over the forecast period.
Dialysis procedures require central venous catheter (CVC), hence, increasing prevalence of chronic kidney diseases and significant number of dialysis procedures in the region is expected to drive the growth of I.V. dressing market near the future
According to Brazilian Journal of Nephrology, in 2016, there were 834 registered dialysis centers, among which 747 dialysis centers were active for chronic dialysis programs. According to the Brazilian Journal of Nephrology, in 2017, an estimated 126,583 Brazilian patients were receiving dialysis treatment.
I.V. Dressing Market Report Coverage
||Market Size in 2021:
||US$ 724.2 Mn
|Historical Data for:
||2017 to 2020
||2021 to 2028
|Forecast Period 2021 to 2028 CAGR:
||2028 Value Projection:
||US$ 1,068.8 Mn
- North America: U.S. and Canada
- Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
- Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
- Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
- Middle East: GCC Countries, Israel, and Rest of Middle East
- Africa: South Africa, North Africa, and Central Africa
- By Product Type: Transparent, Translucent
- By End User: Hospital, Clinics, Others
Becton, Dickinson and Company, Lohmann & Rauscher, Komal Health Care Pvt. Ltd., Paul Hartmann AG, DeRoyal Industries Inc., Tytex, Shandong Dermcosy Medical Co., Ltd., Smith & Nephew plc, Dynarex Corporation, Talent Healthcare, 3M, and Datt Mediproducts Pvt. Limited
- Rising Incidence of Blood Infections And Number of Surgeries
- Increasing Product Approvals And Launches
|Restraints & Challenges:
- Complications Associated with I.V. Dressing
Figure 2. Global I.V. Dressing Market Share (%), by Product Type, 2021
Moreover, I.V. dressing market is expected to witness significant growth over the forecast period, owing to increasing number of surgeries that mostly requires I.V. dressing. For instance, according to National Health Statistics Report of 2017, an estimated 48.3 million surgical and non-surgical procedures were performed in the U.S., also in 2017. An estimated 25.7 million (53%) ambulatory surgery procedures were performed in hospitals and 22.5 million (47%) were performed in ambulatory surgical centers in the U.S.
Global I.V. Dressing Market– Impact of Coronavirus (COVID-19) Pandemic- COVID-19 Considerations for clinical management in the Catheterization Laboratory
The worldwide pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has placed enormous strain on the health care systems of the nations where it has spread widely, with specific implications on practice in the catheterization laboratory. These implications include how modifications in standard practice for cardiac patients are needed for those who are suspected to have COVID-19, and those with COVID-19.
At this time, to preserve hospital bed capacity, it would seem reasonable to avoid elective procedures on patients with significant comorbidities or in whom the expected length of stay is >1 to 2 days (or anticipated to require the intensive care unit). Examples of procedures to defer include:
- Percutaneous coronary intervention for stable ischemic heart disease
- Endovascular intervention for iliofemoral disease in patients with claudication and
- Patent foramen ovale closure
Case decisions should be individualized, taking into account the risk for COVID-19 exposure versus the risk for delay in diagnosis or therapy
In a patient with known COVID-19 and ST-segment elevation myocardial infarction (STEMI), the balance of exposure of staff to the patient and patient benefit in terms of faster diagnosis and management will need to be weighed carefully
Fibrinolysis can be considered an option for a relatively stable patient with STEMI with active COVID-19. In patients with active COVID-19 in whom primary percutaneous coronary intervention is to be performed, appropriate personal protective equipment should be worn, including gown, gloves, goggles (or shields), and an N95 mask, especially given the limited ability to take a history from such patients as well as the potential for clinical deterioration in those with STEMI
Global I.V. Dressing Market Restraint
Complications associated with I.V. dressing are expected to hinder growth of the global I.V. dressing market. These complications include nausea, swelling, discomfort, and others. The most frequently reported peripheral intravenous catheter (PIVC) related complications include phlebitis, infiltration, obstruction, extravasation, accidental removal, and tube clogging.
Moreover, bacterial contamination of the I.V. dressing is also expected to limit growth of the market. Phlebitis is one of the most common complications of peripheral IV therapy, which puts the patient at an increased risk of erythema, pain, swelling, localized infection, and catheter-related bloodstream infections. Some of these complications include nasopharyngeal discomfort, pharyngeal or esophageal perforation, intraperitoneal bleeding, peristomal leaks, and gastrocolic fistula formation.
Major players operating in the global I.V. dressing market include Becton, Dickinson and Company, Lohmann & Rauscher, Komal Health Care Pvt. Ltd., Paul Hartmann AG, DeRoyal Industries Inc., Tytex, Shandong Dermcosy Medical Co., Ltd., Smith & Nephew plc, Dynarex Corporation, Talent Healthcare, 3M, and Datt Mediproducts Pvt. Limited